A new cost-effective production method for creating a biorenewable platform could be used to make new drugs and sustainable plastics at an industrial scale, according to researchers from the University of Texas at Austin.

The team of chemical engineers manipulated a yeast named Y. lipolytica to increase production of triacetic acid lactone (TAL)—a polyketide that forms the biorenewable platform—to levels that far exceed current bioproduction methods.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

This was accomplished by rewiring the yeast’s metabolism, using synthetic biology and genetic engineering. The result was a tenfold increase in production capacity.

Biorenewable platforms are produced from materials such as biomass sugars, as opposed to environmentally-unfriendly petroleum starting materials.

According to lead scientist professor Hal Alper, from the McKetta Department of Chemical Engineering, biorenewables give a ‘greener label to products as well as a cleaner and more precise conversion that is enantiomerically pure.’

Currently there are more than 20 drugs derived from polyketides on the market, including immunosuppressants, statins and antimicrobials.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

However, polyketides—a class of naturally derived molecules that can be used to make many useful products, such as nutritional supplements, speciality pigments and pharmaceuticals—have traditionally suffered from limited product yields.

These poor yields have meant that biorenewables have been financially unviable for mass production.

However, Alper hopes that the technology can ‘open up new product and industrial opportunities in the chemical and pharmaceutical spaces.’

Using their new method, the researchers were able to purify TAL directly from a bioreactor to make a new plastic material that can be formed into a relatively transparent, orange-hued film.

The UT Austin Office of Technology Commercialization has filed US patent applications for the technology, is working to secure worldwide patents, and is seeking commercial partners interested in improving the economics of polyketide production or creating new materials or products from them.

“An important role for our institution, as one of the nation’s leading public research universities, is to move UT Austin’s research from the laboratory to useful products and services for the marketplace,” said Dan Sharp, director of the UT Austin Office of Technology Commercialization.

“Research like this addresses that priority and provides society with innovative solutions that grow our economy and improve the quality of life.”

The findings were published in the journal Proceedings of the National Academy of Sciences.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact